In particular, patients with disseminated Talaromyces marneffei infection or histoplasmosis should be screened for AIGAs, patients with Cryptococcus gattii infection for anti-GM-CSF antibodies, and patients with chronic mucocutaneous candidiasis for anti-IL-17A/F (IL-22), where possible. Here, IL22 is linked to chronic mucocutaneous candidiasis.